Fulcrum Therapeutics, Inc.’s EV / EBITDA at a glance
Fulcrum Therapeutics, Inc. reports ev / ebitda of -13.3x for Dec 2024. The prior period recorded -3.7x (Dec 2023). Year over year the metric moved −9.57 (−260.3%). The rolling three-period average stands at -6.6x. Data last refreshed Dec 7, 2025, 2:47 AM.
Latest reading
-13.3x · Dec 2024
YoY movement
−9.57 (−260.3%)
Rolling average
-6.6x
Current EV / EBITDA
-13.3x
−9.57
−260.3%
Rolling average
-6.6x
Latest Value
-13.3x
Dec 2024
YoY Change
−9.57
Absolute
YoY Change %
−260.3%
Rate of change
3-Period Avg
-6.6x
Smoothed
Narrative signal
Fulcrum Therapeutics, Inc.’s ev / ebitda stands at -13.3x for Dec 2024. Year-over-year, the metric shifted by −9.57, translating into a −260.3% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How ev / ebitda shapes Fulcrum Therapeutics, Inc.'s story
As of Dec 2024, Fulcrum Therapeutics, Inc. reports ev / ebitda of -13.3x. Use EV/EBITDA to benchmark acquisition multiples, leverage-adjusted valuation, and comparable transaction ranges.
Why EV/EBITDA matters
It normalizes valuation across different leverage levels, making it a go-to metric for M&A and cross-company comparisons.
Watch for cyclical swings
EBITDA can swing with cycle-sensitive businesses. Track multi-year averages and peak vs. trough to understand value ranges.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
98%
Operating Margin
-27.4%
Net Profit Margin
-12.2%
Return on Equity
-4%
Return on Assets
-3.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Fulcrum Therapeutics, Inc. (FULC) FAQs
Answers tailored to Fulcrum Therapeutics, Inc.’s ev / ebitda profile using the latest Financial Modeling Prep data.
What is Fulcrum Therapeutics, Inc.'s current ev / ebitda?
As of Dec 2024, Fulcrum Therapeutics, Inc. reports ev / ebitda of -13.3x. This reading reflects the latest filings and price data for FULC.
How is Fulcrum Therapeutics, Inc.'s ev / ebitda trending year over year?
Year-over-year, the figure shifts by −9.57 (−260.3%). Pair this context with revenue growth and free cash flow signals to gauge momentum for FULC.
Why does ev / ebitda matter for Fulcrum Therapeutics, Inc.?
The enterprise value to EBITDA ratio evaluates valuation relative to operating cash flow before capital structure impacts. For Fulcrum Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Fulcrum Therapeutics, Inc.'s ev / ebitda above its recent average?
Fulcrum Therapeutics, Inc.'s rolling three-period average sits at -6.6x. Comparing the latest reading of -13.3x to that baseline highlights whether momentum is building or fading for FULC.
How frequently is Fulcrum Therapeutics, Inc.'s ev / ebitda refreshed?
Data for FULC was last refreshed on Dec 7, 2025, 2:47 AM and updates automatically every 24 hours, keeping your valuation inputs current.